Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (116)	11/5/2007 4:24:37 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 161

Rather subdued response; biz.yahoo.com Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma Monday November 5, 9:00 am ET Tumor Reductions Achieved in More Than 75% of Patients, Including Four Partial Responses, Through Treatment by New Class of Antibody-Drug Conjugate BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN - News) today announced positive data from an ongoing phase I trial of SGN-35, a proprietary antibody-drug conjugate (ADC) product candidate. Multiple objective responses have been observed at well-tolerated doses of SGN-35 in patients with relapsed or refractory Hodgkin lymphoma and other CD30-positive malignancies. The data were reported today at the 7th International Symposium on Hodgkin Lymphoma in Cologne, Germany. ADVERTISEMENT More than 75 percent of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses. Twelve additional patients had stable disease and seven had progressive disease. Of the four patients with partial responses, three are continuing on study, including one patient who has been receiving treatment for more than seven months. SGN-35 has been generally well-tolerated and the maximum tolerated dose has not yet been defined. The majority of adverse events were Grade 1 and 2, and are consistent with antibody administration. Dose-escalation has continued to 2.7 milligrams per kilogram (mg/kg). “These results are particularly encouraging given that relapsed or refractory Hodgkin lymphoma is difficult to treat, especially in patients who relapse after stem cell transplantation,” said Anas Younes, M.D., Professor of Medicine and Director, Clinical and Translational Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center, and presenting investigator of the phase I study. “There are no approved drugs in this setting and no curative therapies. The objective responses observed in this trial support further investigation of SGN-35 towards developing a treatment option to address this unmet medical need.” SGN-35 comprises an anti-CD30 antibody joined by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics’ proprietary ADC technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect. Data were reported on twenty three patients in the single-arm phase I clinical trial who received escalating doses of SGN-35 starting at 0.1 mg/kg up to 1.8 mg/kg administered every three weeks. Of the 23 patients, 21 had Hodgkin lymphoma, one had angioimmunoblastic T-cell lymphoma and one had anaplastic large cell lymphoma. Enrolled patients had received a median of three prior chemotherapies, with 78 percent having received a prior autologous stem cell transplant. “These data not only demonstrate the therapeutic potential of SGN-35 in the treatment of Hodgkin lymphoma, but also underscore the impact that our ADC technology can have in empowering antibodies for the treatment of cancer,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Based on these encouraging data, we are continuing with dose-escalation and planning future studies with SGN-35 to optimize dose and schedule, both as a single-agent and in combination with other agents.” A downloadable copy of Seattle Genetics’ SGN-35 poster will be available from the “Clinical” section of the company’s website at www.seattlegenetics.com. In addition to SGN-35, Seattle Genetics is developing two other proprietary ADC programs, SGN-75, an anti-CD70 ADC, and an anti-CD19 ADC. Both ADCs have demonstrated potent antitumor activity at well tolerated doses in preclinical cancer models.